Clinical trials: Sclerosis
Lymphoma
Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- H10 (NCT00433433)
- Testing
- ABVD q4 weeks, BEACOPP escalated q3 weeks, IN-RT 30 Gy (+ boost 6 Gy residual)
- Where
- Netherlands
- Volunteers
- 1,952 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Sclerosis
REbif FLEXible Dosing in Early Multiple Sclerosis (MS)
The study is a 24 months randomized, double-blind, Placebo-controlled, multi-center clinical trial with an optional 12 months open label extension.
- Trial name
- REFLEX (NCT00404352)
- Testing
- RNF
- Where
- 67 sites in Argentina, Australia and 25 more
- Volunteers
- 517 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
PARKINSON DISEASE (Disorder), Multiple Sclerosis
Cognitive Recovery Via Sensor-based Robotic Upper Limb Rehabilitation in Neurological Disorders
The goal of this clinical trial is to learn if sensor-based robotic upper limb rehabilitation can improve cognitive and motor functions in adults with neurological and neurodegenerative disorders, including Parkinson's disease…
- Conditions
- PARKINSON DISEASE (Disorder), Multiple Sclerosis, Stroke, Neurological Disorders
- Trial name
- CROSS-ND (NCT07384143)
- Testing
- Sensor-Based Robotic Rehabilitation with Cognitive Tasks (SBRR), Standard Conventional Therapy
- Where
- Italy
- Volunteers
- 189 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Multiple Sclerosis
Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.
The goal of this observational study is to evaluate the slowing/reduction of cognitive dysfunction progression and to evaluate grey matter (GM) and thalamus structural changes in Relapsing-Remitting Multiple Sclerosis (RRMS)…
- Trial name
- NCT05811949
- Testing
- Dimethyl Fumarate 240 MG [Tecfidera]
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Facial Angiofibroma
Topical Rapamycin and Calcitriol for Angiofibroma of Tuberous Sclerosis
The aim of the study is to determine the effect and safety of topical rapamycin or calcitriol and their combination for the treatment of TSC-associated facial angiofibroma.
- Trial name
- NCT03140449
- Testing
- Rapamycin, Calcitriol, Rapamycin-calcitriol combination
- Volunteers
- 52 people
- Sponsor
- National Taiwan University Hospital
Relapsing-Remitting Multiple Sclerosis
Assessment of Attentional and Executive Disorders in Multiple Sclerosis Using Techniques of Virtual Reality
Since many years cognitive disorders are a main topic of clinical research in Multiple Sclerosis (MS) as there could be observed early on in the disease and could induce with time in patients significant socio-professional…
- Trial name
- SEPREV (NCT01805336)
- Testing
- Assessment of attentional functions by traditional tests, Assessment of attentional functions by virtual reality tests, Assessment of executive functions by traditional tests
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Functional Neurological Disorders, Multiple Sclerosis
Assessment of the Frequency of Functional Neurological Disorders in Multiple Sclerosis and Analysis of Clinical and Psychological Determinants
Multiple sclerosis (MS) and functional neurological disorders (FND) share clinical features, which may result in FND being overlooked in patients with MS.
- Trial name
- FTNF-SEP (NCT07849816)
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Spasticity, Multiple Sclerosis
Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.
The purpose of this study is to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis.
- Trial name
- NCT01868048
- Testing
- Sativex
- Sponsor
- GW Research Ltd
Multiple Sclerosis
Propionic Acid for Multiple Sclerosis: Safety and Benefits
The purpose of this study is to explore the long-term safety, tolerability, and clinical efficacy of propionic acid as an add-on therapy in multiple sclerosis (MS).
- Trial name
- Pro-MADAI (NCT07595081)
- Testing
- Propionic acid 1000 mg capsule
- Where
- Austria
- Volunteers
- 22 people
- Sponsor
- Salzburger Landeskliniken
Amyotrophic Lateral Sclerosis (ALS)
Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial
The purpose of this research is to investigate the validity of a previous clinical trial named EH301, which showed beneficial effects of anti-oxidant therapies in patients with amyotrophic lateral sclerosis (ALS).
- Trial name
- MICABO-ALS (NCT04244630)
- Testing
- Antioxidants
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dallas VA Medical Center
Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis
Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy
Background: Multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML) are disorders that affect the central nervous system (CNS). The CNS includes the brain, spinal cord, and optic nerves.
- Conditions
- Progressive Multifocal Leukoencephalopathy, Multiple Sclerosis, Other Neuroinflammatory Diseases With BBB Leakage
- Trial name
- NCT05849467
- Testing
- 89 Zr-Df-crefmirlimab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Interstitial Lung Disease With Systemic Sclerosis
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
The goal of this clinical trial is to evaluate the efficacy on lung function after 24 weeks of rituximab + MMF combination comparatively to placebo + MMF combination in patients with SSc-ILD severe at the initial assessment or at…
- Trial name
- EVER-ILD 3 (NCT06549231)
- Testing
- Rituximab
- Where
- France
- Volunteers
- 102 people
- Sponsor
- University Hospital, Tours
Multiple Sclerosis
Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course
Chart review.
- Trial name
- NCT02301572
- Where
- United States
- Volunteers
- 750 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Sclerosis
Therapy Optimization in Multiple Sclerosis (MS)
The purpose of this study is to determine if higher compliance and adherence rates to drug therapy for MS result in better health outcomes than lower rates of therapy compliance and adherence.
- Trial name
- TOP MS (NCT00819000)
- Testing
- Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b
- Where
- 3 sites in United States
- Volunteers
- 2,878 people
- Sponsor
- Teva Neuroscience, Inc.
ALS
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to determine the safety and tolerability of RNS60 in patients with Amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT02525471
- Testing
- RNS60
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sabrina Paganoni, M.D.
Multiple Sclerosis
Using Motor Imagery-based Brain-computer Interface With Multiple Sclerosis Patients.
The goal of this clinical trial is to evaluate the effectiveness of a wearable brain-computer interface (BCI)-based neurofeedback system using motor imagery (MI) to support upper limb motor rehabilitation in patients with…
- Trial name
- BCI_MI_SM_2026 (NCT07472556)
- Testing
- Brain Computer Interface
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Pasquale Arpaia
Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis
MUSCLE - Nordic Walking in MUltiple SCLErosis
The aim of the study is to analyze the effects of Nordic Walking and free walking in the clinical-functional, postural balance, motor control, muscular echographic quality, and gait analysis (pendulum gait mechanism), in people…
- Conditions
- Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
- Trial name
- MUSCLE (NCT05385731)
- Testing
- Nordic Walking (NWG), Free Walking (FWG), Health Education (HEG)
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Leonardo A. Peyré-Tartaruga
Multiple Sclerosis, Relapsing-Remitting
Pilot Test of ACTOS in Multiple Sclerosis: Safety and Tolerability
The purpose of this study is to determine whether an already FDA approved drug is safe and tolerable in Relapsing Remitting Multiple Sclerosis patients.
- Trial name
- NCT00242177
- Testing
- ACTOS (Pioglitazone)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Illinois at Chicago
ALS (Amyotrophic Lateral Sclerosis)
ALS Reversals - Lunasin Regimen
This is a 12-month, widely inclusive, largely virtual, single-center, open-label pilot trial utilizing a historical control group.
- Trial name
- NCT02709330
- Testing
- Lunasin Regimen, Historical control
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Multiple Sclerosis
Relıabılıty and valıdıty of the supıne-to-stand Test wıth Multiple Sclerosis
Background: Supine-to-Stand Test (SST) requires muscle strength, flexibility, and dynamic balance and can be used as a marker of functional motor competence in patients with Multiple Sclerosis (pwMS).
- Trial name
- NCT06790992
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Sanko University